Latest Strategic Shift News

Yari Minerals has secured approvals to begin drilling at its Rolleston South Coal Project, aiming to upgrade its substantial coal resource and confirm metallurgical quality.

Mammoth Minerals has initiated its first-ever diamond drilling campaign at the Excelsior Gold-Silver Project in Nevada, aiming to unlock detailed geological insights and advance metallurgical testing. Meanwhile, the company has deferred payment terms on its Skyline Copper Project in Canada as it sharpens focus on US gold assets.

Pioneer Lithium refines its exploration focus, prioritizing its US uranium projects with Skull Creek nearing drill readiness, while withdrawing from a Namibian uranium asset to optimize capital and value creation.

Excite Technology Services has shattered its previous sales record, achieving $7.14 million in contract value for September 2025, driven by strong demand in cybersecurity and digital forensics.

Gold Mountain Limited has voluntarily suspended trading on the ASX pending an announcement that will update the issue price of a recent capital raising placement.

Dyno Nobel has finalised the sale of its Fertilisers Distribution business and is advancing strategic shifts including a new US TNT manufacturing partnership, underpinning a strong FY25 outlook.

Vanadium Resources Limited has appointed mining entrepreneur Nick Diack as CEO to spearhead the transition of its Steelpoortdrift Vanadium Project towards near-term production, signaling a strategic shift backed by strong industry expertise and performance-linked incentives.

Perseus Mining has confirmed Craig Jones as its new Managing Director and CEO, effective October 1, 2025, following Jeff Quartermaine's retirement. This leadership transition marks a new chapter for the gold miner.

Energy World Corporation’s final audited results for FY25 reveal a major loan-to-equity reclassification and a reshuffle of director fee liabilities, reshaping the company’s balance sheet.

Uscom Limited has struck a deal to sell its entire business to Singapore-based AXO Medtech VCC for $2.59 million, aiming to unlock capital for growth under new ownership. Shareholder approval is the next critical step before the transaction can proceed.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

Invex Therapeutics has discontinued exclusive negotiations to acquire a rare neurological disease company due to board instability triggered by a shareholder requisition notice. Despite this setback, the company remains committed to diversifying its neurological treatment portfolio.